{"id":"ocs-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Conjunctival hemorrhage"},{"rate":"5-10%","effect":"Eye pain"},{"rate":"5-10%","effect":"Increased intraocular pressure"}]},"_chembl":{"chemblId":"CHEMBL3693887","moleculeType":"Small molecule","molecularWeight":"478.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to VEGF and preventing its interaction with its receptor, thereby inhibiting angiogenesis and reducing vascular permeability. This mechanism is thought to be beneficial in treating conditions characterized by excessive angiogenesis, such as age-related macular degeneration.","oneSentence":"OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:32.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of neovascular (wet) age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT04130802","phase":"PHASE2","title":"OCS-01 in Treating Inflammation and Pain in Post-cataract Patients","status":"COMPLETED","sponsor":"Oculis","startDate":"2019-09-27","conditions":"Inflammation Corneal, Pain, Postoperative","enrollment":153},{"nctId":"NCT05147233","phase":"PHASE3","title":"A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Oculis","startDate":"2022-06-24","conditions":"Inflammation Eye Pain, Postoperative Cataract","enrollment":241},{"nctId":"NCT05608837","phase":"PHASE2","title":"Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quan Dong Nguyen","startDate":"2023-05-26","conditions":"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative","enrollment":28},{"nctId":"NCT06128369","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery","status":"TERMINATED","sponsor":"Oculis","startDate":"2023-12-18","conditions":"Inflammation Eye, Pain, Postoperative, Cataract","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dexamethasone ophthalmic suspension eye drops"],"phase":"phase_3","status":"active","brandName":"OCS-01","genericName":"OCS-01","companyName":"Oculis","companyId":"oculis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor. Used for Treatment of neovascular (wet) age-related macular degeneration.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}